Rinatabart sesutecan (Rina-S)

Antibody–drug conjugate

Also known as PRO1184, GEN1184

Phase 3topline reported

Evidence outlook

Ovarian Cancer: topline reported 2026-10-23

The sponsor reported topline results on 2026-10-23 (Phase 3 RAINFOL-02 (NCT06619236) met PFS and key secondary OS). The announcement is listed under Regulatory events.

Latest reported trial: RAINFOL-02 (NCT06619236) · Phase 3 · met primary endpoint · grade pending

Also in development:Non-Small Cell Lung Cancer · Phase 2HR+/HER2- Metastatic Breast Cancer · Phase 1/2Endometrial Cancer · Phase 3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Endometrial Cancer
Ovarian Cancer
NCT07604766 · Genmab
2026-06-26 – 2028-12 · Platinum-resistant Ovarian Cancer
What this study did
Phase 2 (2)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07539311 · Genmab
2026-05-11 – 2028-11 · Gastrointestinal Cancers
What this study did
Phase 1/2 (1)
HR+/HER2- Metastatic Breast Cancer

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Endometrial Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rinatabart Sesutecan (Rina-S): this drugPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
DostarlimabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023).
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 3Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SelinexorPhase 3Small moleculeXPO1 (exportin-1)not yet gradedNo reviewed efficacy summary in this indication
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
SerabelisibPhase 2Small moleculePI3K alpha (inhibitor)Weak signalNo reviewed efficacy summary in this indication
IMGN-151Phase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rinatabart sesutecan (Rina-S) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2027-09 · NCT07604766 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-22 · NCT07288177 · CT.gov ↗
What to watch
2028 (3)
September 2028 (1)
Phase 2Gastrointestinal CancersRecruiting
Est. primary completion 2028-09 · NCT07539311 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-10 · NCT07225270 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT05579366 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-08 · NCT07166094 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2029-12 · NCT07564141 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Phase 3Ovarian CancerNot yet recruiting
Est. primary completion 2030-03 · NCT07859215 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026Topline resultPhase 3 RAINFOL-02 (NCT06619236) met PFS and key secondary OS
Genmab · Source ↗